Associated Papers
PDE11A Is a Phenotype Modulator of Primary Bilateral Macronodular Adrenal Hyperplasia: Results of a 334-Patient Series.
Vaduva P et al.
The Journal of Clinical Endocrinology and Metabolism, 2025
Germline targeted next-generation sequencing in patients with adrenal incidentalomas.
Messina E et al.
Frontiers in Endocrinology, 2025
Detection of germline variants with pathogenic potential in 48 patients with familial colorectal cancer by using whole exome sequencing.
Singh AK et al.
Bmc Medical Genomics, 2023
37296477 (PubMed )
Supplement: 12920_2023_1562_MOESM3_ESM.xlsx › Stage3.1-Class3_variants
Primary bilateral macronodular adrenal hyperplasia: definitely a genetic disease.
Cavalcante IP et al.
Nature Reviews. Endocrinology, 2022
Phosphodiesterase 11A (PDE11A) gene defects in patients with acth-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors.
Vezzosi D et al.
The Journal of Clinical Endocrinology and Metabolism, 2012
Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer.
Faucz FR et al.
The Journal of Clinical Endocrinology and Metabolism, 2011
Select a paper to view details